دورية أكاديمية
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer.
| العنوان: | The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. |
|---|---|
| المؤلفون: | Detterbeck FC; Department of Surgery, Yale University School of Medicine, New Haven, Connecticut. Electronic address: frank.detterbeck@yale.edu., Ostrowski M; Department of Thoracic Surgery, Medical University of Gdansk, Gdansk, Poland., Hoffmann H; Division of Thoracic Surgery, Department of Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany., Rami-Porta R; Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain., Osarogiagbon RU; Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee., Donnington J; Department of Surgery, University of Chicago, Chicago, Illinois., Infante M; Department of Thoracic Surgery, Ospedale Borgo Trento, Verona, Italy., Marino M; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Marom EM; Department of Diagnostic Imaging, The Chaim Sheba Medical Center, Ramat Gan, Israel., Nakajima J; Department of Thoracic Surgery, The University of Tokyo, Tokyo, Japan., Nicholson AG; Department of Histopathology, Royal Brompton and Harefield NHS Hospitals, Guy's and St. Thomas' NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom., van Schil P; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem (Antwerp), Belgium., Travis WD; Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York., Tsao MS; Department of Pathology, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Edwards JG; Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals National Health Service Foundation Trust, Northern General Hospital, Sheffield, United Kingdom., Asamura H; Division of Thoracic Surgery, Keio School of Medicine, Tokyo, Japan. |
| مؤلفون مشاركون: | Members of the Staging and Prognostic Factors Committee and Advisory Boards |
| المصدر: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jul; Vol. 19 (7), pp. 1052-1072. Date of Electronic Publication: 2024 Apr 01. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : New York, NY : Elsevier Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2006- |
| مواضيع طبية MeSH: | Lung Neoplasms*/surgery , Lung Neoplasms*/pathology , Lung Neoplasms*/classification , Neoplasm Staging*/methods , Neoplasm, Residual*/pathology, Humans |
| مستخلص: | Introduction: The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind. For lung cancer, an additional category encompasses situations in which the presence of residual tumor is uncertain. Methods: This paper represents a comprehensive review of evidence regarding these R categories and the descriptors thereof, focusing on studies published after the year 2000 and with adjustment for potential confounders. Results: Consistent discrimination between complete, uncertain, and incomplete resection is revealed with respect to overall survival. Evidence regarding specific descriptors is generally somewhat limited and only partially consistent; nevertheless, the data suggest retaining all descriptors but with clarifications to address ambiguities. Conclusion: On the basis of this review, the R-classification for the ninth edition of stage classification of lung cancer is proposed to retain the same overall framework and descriptors, with more precise definitions of descriptors. These refinements should facilitate application and further research. Competing Interests: Disclosure Drs. Asamura, Detterbeck, Edwards, Hoffmann, Infante, Marino, Nakajima, Ostrowski, Rami-Porta, Travis have nothing to disclose.Dr. Van Schil reports personal fees from BMS, personal fees from MSD, personal fees from Roche, from Janssen, outside the submitted work; and BACTS (Belgian Association for Cardiothoracic Surgery) treasurer - no fees, IASLC (International Association for the Study of Lung Cancer) president 2023-2025 - no feesDr. Tsao reports grants and personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from Sanofi, personal fees from Daiichi Sankyo, personal fees from Amgen, personal fees from Abbvie, outside the submitted workDr. Donington reports Amgen: advisory board, AstraZeneca: advisory board and speaker, BMS: advisory board and speaker, Merck: advisory board and speaker, Roche/Genentech: advisory board and speaker.Dr. NICHOLSON reports personal fees from MERCK, personal fees from BOEHRINGER INGELHEIM, grants and personal fees from PFIZER, personal fees from NOVARTIS, personal fees from ASTRA ZENECA, personal fees from BRISTOL MYER SQUIB, personal fees from ROCHE, personal fees from ASTRA ZENECA, personal fees from ABBVIE, personal fees from ONCOLOGICA, personal fees from UPTODATE, personal fees from EUROPEAN SOCIETY OF ONOCLOGY, personal fees from LIBERUM, personal fees from TAKEDA UK, personal fees from SANOFI, outside the submitted work; .Dr. Marom reports other from boehringer ingelheim, other from AstraZeneca, other from Merck Sharp & Dohme, outside the submitted work; Raymond U. Osarogiagbon reports grants from National Cancer Institute, during the conduct of the study; personal fees from American Cancer Society, personal fees from Biodesix, personal fees from Genentech/Roche, personal fees from Lungevity Foundation, personal fees from National Cancer Institute, personal fees from Tryptych Healthcare Partners, personal fees from AstraZeneca, personal fees from GE Healthcare, personal fees from Eli Lilly, personal fees from Gilead Sciences, personal fees from Pfizer, outside the submitted work; In addition, Dr. Osarogiagbon has a patent Lymph node specimen collection kit issued, and a patent Method for collecting lymph nodes issued and Board Chair, Hope Foundation for Cancer Research (SWOG); Board of Scientific Advisors, National Cancer Institute; Steering Committee, National Lung Cancer Roundtable; Scientific Advisory Board, Lung Cancer Foundation of America; Scientific Advisory Board, GO2 Foundation; Scientific Advisory Board, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center; Scientific Advisory Board, LUNGevity Foundation. Founder, Oncobox Devices, Inc. (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Complete resection; Lung cancer; Residual disease; Surgery |
| تواريخ الأحداث: | Date Created: 20240403 Date Completed: 20240707 Latest Revision: 20240707 |
| رمز التحديث: | 20240708 |
| DOI: | 10.1016/j.jtho.2024.03.021 |
| PMID: | 38569931 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1556-1380 |
|---|---|
| DOI: | 10.1016/j.jtho.2024.03.021 |